DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first ...

Tibsovo is already approved in the US as a monotherapy for previously-untreated IDH1-positive AML, as well as for patients with the cancer who have relapsed or are refractory to prior treatment ...

IDH1 mutations are seen in between 7% and 14% of AML patients – which is the most common form of leukaemia in adults with around 20,000 new cases in the US each year – and tend to be ...

Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review; Kura ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an ... of newly diagnosed acute myeloid leukemia (AML), relapsed or refractory AML, relapsed or refractory ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an ... of newly diagnosed acute myeloid leukemia (AML), relapsed or refractory AML, relapsed or refractory ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...